RCT | Adjunctive Cariprazine for the treatment of patients with major depressive disorder

Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study – American Journal of Psychiatry (link to abstract – $ for full-text)

Commentary on Twitter

RCT: Adjunctive cariprazine (1.5 mg/d) demonstrated efficacy in reducing depressive symptoms in adults with MDD and inadequate response to ADs vs. placebo at week 6 (−14.1 vs. −11.5) https://t.co/k4QST25FeF

— PfOL (@psychopharmacol) March 3, 2023